#USA #San Francisco #Cancer Immunotherapy #Parker Institute #Maria Olson

Maria Olson Appointed as Chief Advancement Officer at PICI

The Parker Institute for Cancer Immunotherapy (PICI) has made a significant move in its mission to revolutionize cancer treatment with the appointment of Maria Olson as the new Chief Advancement Officer. With over two decades of experience in the nonprofit sector, Olson brings extensive expertise in leading transformative fundraising and donor engagement strategies.

As PICI aims to accelerate the pace of groundbreaking cancer research, Olson will spearhead the organization’s global philanthropic efforts. Her role is critical as PICI seeks to develop innovative cancer immunotherapies and deliver these life-saving treatments to patients. The institute has consistently engaged in groundbreaking research since its inception, and Olson's contributions are expected to strengthen the momentum.

Dr. Karen E. Knudsen, CEO of PICI, praised Olson's remarkable blend of strategic vision and hands-on fundraising expertise. “Maria brings an exceptional combination of strategic vision, fundraising expertise, and a deep understanding of what it takes to build lasting relationships with donors and partners,” said Dr. Knudsen. Her leadership will be essential for fostering the philanthropic community that will help to champion bold ideas and support vital research.

Before her transition to PICI, Olson held the position of Executive Vice President at the American Cancer Society, where she led fundraising efforts that resulted in a remarkable growth in revenue, increasing from $44 million to $85 million in just three years. She successfully oversaw a diverse portfolio estimated at $250 million and played a pivotal role in coordinating strategic partnerships and securing transformational gifts.

Olson’s impressive tenure also includes significant contributions to the American Heart Association, where she directed a $60 million operation while managing successful teams across multiple sectors. Her prior roles also include leadership positions at the Cystic Fibrosis Foundation and strategic roles at notable firms like Chase Manhattan Bank and J. Walter Thompson USA.

“I am honored to join the Parker Institute for Cancer Immunotherapy at such an important moment in the fight against cancer,” Olson remarked. She expressed excitement about PICI's collaborative approach and the commitment to translating scientific breakthroughs into real-world advances for patients. Olson’s vision for establishing strong partnerships and securing necessary philanthropic support will aim to bridge gaps in cancer treatment.

The Parker Institute, established in 2016, operates as a 501c3 nonprofit organization dedicated to transforming cancer from a devastating diagnosis to a curable condition through pioneering immune therapies. With a strategy that unites prestigious cancer centers into a cohesive consortium, PICI focuses on high-risk, high-reward science. The way PICI operates transcends traditional research models by actively promoting innovations through clinical trials and company formations, directly targeting patient access.

To date, PICI has supported over 1,000 researchers and boasts a diverse portfolio that includes 17 biotech ventures, having raised more than $4 billion in capital. The organization is not just focused on scientific excellence; it is also committed to executing entrepreneurial approaches that expedite the development of cancer cures.

In conclusion, the appointment of Maria Olson marks an exciting new chapter for PICI. Her extensive experience and proven track record position her as a key figure in the ongoing pursuit of advancing cancer immunotherapies. As she steps into this pivotal role, the expectations are high, with the promise of innovative treatments on the horizon. The PICI community eagerly anticipates the influence Olson will have on enriching its philanthropic landscape and fostering the partnerships necessary for groundbreaking progress in cancer research.